These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16863453)

  • 1. Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.
    Sahi J
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):409-27. PubMed ID: 16863453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity.
    Feng B; El-Kattan AF; Radi ZA
    Curr Protoc Toxicol; 2012 Aug; Chapter 23():Unit 23.3.1-15. PubMed ID: 22896010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
    Chu X; Chan GH; Evers R
    J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney.
    Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2009; 24(1):37-52. PubMed ID: 19252335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transporters and renal drug elimination.
    Lee W; Kim RB
    Annu Rev Pharmacol Toxicol; 2004; 44():137-66. PubMed ID: 14744242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transporters and xenobiotic disposition.
    Kim RB
    Toxicology; 2002 Dec; 181-182():291-7. PubMed ID: 12505328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal drug-drug interactions: what we have learned and where we are going.
    Lepist EI; Ray AS
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):433-48. PubMed ID: 22372422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction.
    Mao Q; Lai Y; Wang J
    Drug Metab Dispos; 2018 May; 46(5):561-566. PubMed ID: 29636376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug membrane transporters in the liver: regulation of their expression and activity].
    Fardel O; Payen L; Sparfel L; Vernhet L; Lecureur V
    Ann Pharm Fr; 2002 Nov; 60(6):380-5. PubMed ID: 12514503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of Renal Drug Transporter in Drug Disposition and Renal Toxicity.
    Yang X; Han L
    Adv Exp Med Biol; 2019; 1141():341-360. PubMed ID: 31571169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators.
    Knights KM; Miners JO
    Drug Metab Rev; 2010 Feb; 42(1):63-73. PubMed ID: 19780654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion transporters.
    Tsuji A; Tamai I
    Pharm Biotechnol; 1999; 12():471-91. PubMed ID: 10742985
    [No Abstract]   [Full Text] [Related]  

  • 14. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
    Varma MV; Steyn SJ; Allerton C; El-Kattan AF
    Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renal failure on drug transport and metabolism.
    Sun H; Frassetto L; Benet LZ
    Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
    Okudaira N
    J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal transporters in drug development.
    Morrissey KM; Stocker SL; Wittwer MB; Xu L; Giacomini KM
    Annu Rev Pharmacol Toxicol; 2013; 53():503-29. PubMed ID: 23140242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research.
    Tang H; Shen DR; Han YH; Kong Y; Balimane P; Marino A; Gao M; Wu S; Xie D; Soars MG; O'Connell JC; Rodrigues AD; Zhang L; Cvijic ME
    J Biomol Screen; 2013 Oct; 18(9):1072-83. PubMed ID: 24062352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.
    Scotcher D; Jones C; Posada M; Galetin A; Rostami-Hodjegan A
    AAPS J; 2016 Sep; 18(5):1082-1094. PubMed ID: 27506526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.
    Kusuhara H; Sugiyama Y
    Drug Metab Rev; 2010 Aug; 42(3):539-50. PubMed ID: 20175646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.